Actos Bladder Cancer Link Supported By New Findings

Share Article

Actos bladder cancer link corroborated by new study; long-term users are most at risk, Bernstein Liebhard LLP reports.

Bernstein Liebhard LLP | Consumer Injury Lawyers
They concluded that patients who took Actos for less than five years had double the risk of developing bladder cancer, while those who used the drug for more than five years had over three times the risk.

Actos bladder cancer link confirmed by new study, finding that the risk of bladder cancer increases among patients who are long-term users of the type 2 diabetes drug, Bernstein Liebhard LLP reports.* The study, which was published on August 9, 2012 in the Journal of the National Cancer Institute, concluded that Actos users are two to three times more likely to develop bladder cancer compared to patients taking other classes of diabetes medications. In conducting this latest study, researchers from the University of Pennsylvania analyzed data from 60,000 type 2 diabetes patients in the U.K’s Health Improvement Database from July 1, 2000 and August 31, 2010. They concluded that patients who took Actos for less than five years had double the risk of developing bladder cancer, while those who used the drug for more than five years had over three times the risk.

Bernstein Liebhard LLP, a nationwide law firm representing clients who have been injured by dangerous drugs, is currently offering free and confidential case reviews to individuals who took Actos and have been diagnosed with bladder cancer.

Previous Studies Support Link Between Actos And Bladder Cancer

These latest findings lend further support to a series of similar studies published in recent months concluding that there is, in fact, a link between bladder cancer and long-term Actos use. Within the past two years, Actos concerns have mounted due to a wave of studies, recalls, and warnings:

  •     July 2012: Study published in the Canadian Medical Association Journal concludes that patients taking Actos face a 22 percent increased risk of developing bladder cancer.**
  •     May 2012: Study published in the British Medical Journal concludes that taking Actos for two years can double the risk of developing bladder cancer.***
  •     June 2011: Actos is recalled in France and Germany due to evidence confirming the link between the drug and bladder cancer.
  •     May 2011: U.S. Food and Drug Administration (“FDA”) publishes a study concluding that there is a link between Actos and bladder cancer; the FDA adds a warning label to alert users about Actos side effects.****
  •     September 2010: FDA initiates an investigation to determine whether long-term Actos use puts patients at an increased risk for developing bladder cancer.

Those who developed bladder cancer as a result of taking Actos may be able to collect compensation for medical expenses, lost wages, pain and suffering, and more. Learn more about the Actos litigation by visiting our website, For more information, contact a lawyer at Bernstein Liebhard LLP today at (877) 779-1414.


About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past nine consecutive years. Only two firms in the country have been selected for the Hot List nine years in a row.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(877) 779-1414

ATTORNEY ADVERTISING. © 2012 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Amy L. Abate. Prior results do not guarantee or predict a similar outcome with respect to any future matter.


Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Visit website